Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6456-6466

  Vieth, Michal ^a   Erickson, Jon ^a   Jibo, Wang ^a   Webster, Yue ^a   Mader, Mary ^a   Higgs, Richard ^a   Watson, Ian ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; HYDROPHOBICITY;

COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; PHOSPHOTRANSFERASES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; SOLUBILITY;

EID: 70350046704     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901147e     Document Type: Article

References (33)

1. Grant, S. K. Therapeutic Protein Kinase Inhibitors. Cell. Mol. Life Sci. 2009, 66, 1163-1177.
2. Fabbro, D.; Garcia-Echeverria, C. G. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discovery Dev. 2002, 5, 701-712.
3. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
4. Gill, A. L.; Verdonk, M.; Boyle, R. G.; Taylor, R.AComparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development. Curr Top. Med. Chem. 2007, 7, 1408-1422.
5. Vieth, M.; Siegel, M. G.; Higgs, R. E.; Watson, I. A.; Robertson, D. H.; Savin, K. A.; Durst, G. L.; Hipskind, P. A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 2004, 47, 224-232.
6. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Kinomics: characterizing the therapeutically validated kinase space. Drug Discovery Today 2005, 10, 839-846
7. Sutherland, J. J.; Higgs, R. E.; Watson, I.; Vieth, M. Chemical fragments as foundations for understanding target space and activity prediction. J. Med. Chem. 2008, 51, 2689-2700.
8. Keiser, M.J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007, 25, 197-206.
9. Fernandez, A.; Maddipati, S. A priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem. 2006, 49, 3092-3100.
10. Paolini, G. V.; Shapland, R. H.; van Hoorn, W. P.; Mason, J. S.; Hopkins, A. L. Global mapping of pharmacological space. Nat. Biotechnol. 2006, 24, 805-815.
11. Liew, C. Y. M.; Xiao, H.; Liu, X.; Yap, C. W. SVM Model for Virtual Screening of Lck Inhibitors. J. Chem. Inf. Model. 2009, 49, 877-885.
12. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and Scoring in Virtual Screening for Drug Discovery: Methods and Applications. Nat. Rev. Drug Discovery 2004, 3, 935-949.
13. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432, 862-865.
14. Vieth, M.; Siegel, M. Structural fragments in marketed oral drugs. In Fragment Based Drug Discovery; Erlanson, J., Ed.; Wiley-VCH: Weinheim, 2006; pp 123-135.
15. Joachims, T. Making Large-Scale SVM Learning Practical. In Advances in Kernel Methods - Support Vector Learning; Scholkopf, B.; Burges, C.; Smola, A., Eds.; MIT Press: Cambridge, 1999.
16. Carhart, R. E.; Smith, D. H.; Venkataraghavan, R. Atom pairs as molecular features in structure-activity studies: definition and applications. J. Chem. Inf. Comput. Sci. 1985, 25, 64-73.
17. Doucet, J.-P. B.; Xia, F.; Panaye, H.; Fan, A.; Nonlinear, B. SVM Approaches to QSPR/QSAR Studies and Drug Design. Curr. Comput.-Aided Drug Des. 2007, 3, 263-289.
18. Han, L. Y.; Ma, X. H.; Lin, H. H.; Jia, J.; Zhu, F.; Xuec, Y.; Li, Z. R.; Cao, Z. W.; Ji, Z. L.; Chen, Y. Z. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. J. Mol. Graph. Model. 2008, 26, 1276-1286.
19. Gedeck, P.; Lewis, R. A. Exploiting QSAR models in lead optimization. Curr. Opin. Drug Discovery Dev. 2008, 11, 569-575.
20. Tropsha, A. Variable selection QSAR modeling, model validation, and virtual screening. Annu Rep. Comput. Chem. 2006, 2, 113-126.
21. Sutherland, J. J.; Nandigam, R. K.; Erickson, J. A.; Vieth, M. Lessons in Molecular Recognition. 2. Assessing and Improving Cross-Docking Accuracy. J. Chem. Inf. Model. 2007, 47, 2293-2302.
22. Nandigam, R. K.; Evans, D. A.; Erickson, J. A.; Kim, S.; Sutherland, J. J. Predicting the accuracy of ligand overlay methods with Random Forest models. J. Chem. Inf. Model. 2008, 48, 2386-2394.
23. Dooley, C.; Houghten, R. The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands. Life Sci. 1993, 52, 1509-1517. (Pubitemid 23103737)
24. Cui, J.; Funk, L. A.; Jia, L.; Kung, P.-P.; Meng, J. J.; Nambu, M. D.; Pairish, M. A.; Sheng, H.; Tran-Dube, M. B. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors. PCT Gazette, WO 2006/021886 Al, 2006.
25. Givehchi, A.; Bender, A.; Glen, R. C. Analysis of activity space by fragment fingerprints, 2D descriptors, and multitarget dependent transformation of 2D descriptors. J. Chem. Inf. Model. 2006, 46, 1078-1083.
26. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3727.
27. Chemaxon LogD; ChemAxon Kft: Budapest, 1037 Hungary, 2008; www.chemaxon.com.
28. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics - structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004, 1697, 243-257.
29. Voth, R. A.; Ho, S. P. The Role of Halogen Bonding in Inhibitor Recognition and Binding by Protein Kinases. Curr. Top. Med. Chem. 2007, 7, 1336-1348.
30. Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 2003, 23, 302-321.
31. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature 2004, 432, 855-861. (Pubitemid 40037141)
32. Deanda, F.; Stewart, E. L.; Reno, M. J.; Drewry, D. H. Kinase- Targeted Library Design through the Application of the PharmPrint Methodology. J. Chem. Inf. Model. 2008, 48, 2395-2403.
33. Pellecchia, M. Fragment-based drug discovery takes a virtual turn. Nat. Chem. Biol. 2009, 5, 274-275.